广泛期小细胞肺癌免疫治疗疗效预测
Prediction of Efficacy of Immunotherapy for Extensive Stage Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.1351193, PDF,   
作者: 李斯琴高娃：内蒙古医科大学，第一临床医学院，内蒙古 呼和浩特；呼 群*：内蒙古医科大学附属医院肿瘤内科，内蒙古 呼和浩特
关键词: 小细胞肺癌；免疫治疗；治疗疗效；生物标志物；Small Cell Lung Cancer； Immunotherapy； Therapeutic Efficacy； Biomarker
摘要: 小细胞肺癌(small cell lung cancer, SCLC)是异质性、侵袭性较强的神经内分泌肿瘤。由于SCLC恶性程度极高，极早发生远处转移，且确诊时大多已进入广泛期小细胞肺癌(extensive stage small cell lung cancer, ES-SCLC)。虽然ES-SCLC对化疗极度敏感，但其进展速度极快，故预后极差。因此，为ES-SCLC患者提供新的治疗方案尤为重要。近年来，免疫治疗已经在SCLC治疗方面取得了一些进展。免疫治疗不仅价格昂贵而且有些患者会出现较为严重的不良反应，因此寻找有效生物标记物用来评估患者免疫治疗是否获益从而减轻患者的病痛折磨及经济负担的关键。本研究针对ES-SCLC免疫治疗疗效及预测生物标志物进行综述。
Abstract: Small cell lung cancer (SCLC) is a heterogeneous and aggressive neuroendocrine tumor. Due to the extremely high degree of malignancy of SCLC, distant metastasis occurs very early, and most pa-tients have entered extensive stage small cell lung cancer (ES-SCLC) when diagnosed. Although ES-SCLC is extremely sensitive to chemotherapy, it progresses rapidly and has a poor prognosis. Therefore, it is particularly important to provide new treatment options for patients with ES-SCLC. In recent years, immunotherapy has made some progress in the treatment of SCLC. Immunotherapy is not only expensive but also causes serious adverse reactions in some patients. Therefore, the search for effective biomarkers is the key to evaluating whether patients benefit from immuno-therapy. This study reviews the efficacy and predictive biomarkers of ES-SCLC immunotherapy.
文章引用：李斯琴高娃, 呼群. 广泛期小细胞肺癌免疫治疗疗效预测[J]. 临床医学进展, 2023, 13(5): 8519-8525. https://doi.org/10.12677/ACM.2023.1351193

参考文献

[1] Zhang, W., Girard, L., Zhang, Y.A., et al. (2018) Small Cell Lung Cancer Tumors and Preclinical Models Display Het-erogeneity of Neuroendocrine Phenotypes. Translational Lung Cancer Research, 7, 32-49. [Google Scholar] [CrossRef] [PubMed]
[2] Guo, H., Li, L. and Cui, J. (2020) Advances and Challenges in Im-munotherapy of Small Cell Lung Cancer. Chinese Journal of Cancer Research, 32, 115-128. [Google Scholar] [CrossRef] [PubMed]
[3] 徐瑜, 白莉. 广泛期小细胞肺癌免疫治疗新理念[J]. 中华肺部疾病杂志(电子版), 2021, 14(4): 407-411.
[4] Mathieu, L., Shah, S., Pai-Scherf, L., et al. (2021) FDA Ap-proval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist, 26, 433-438. [Google Scholar] [CrossRef] [PubMed]
[5] 徐张闻笛, 黄华艳, 夏立亮, 等. 广泛期小细胞肺癌免疫治疗疗效预测和增敏策略[J]. 实用肿瘤杂志, 2022, 37(6): 495-500. [Google Scholar] [CrossRef] 
[6] Savage, P.A., Leventhal, D.S. and Malchow, S. (2014) Shaping the Repertoire of Tumor-Infiltrating Effector and Regulatory T Cells. Immunological Reviews, 259, 245-258. [Google Scholar] [CrossRef] [PubMed]
[7] Becker, J.C., Andersen, M.H., Schrama, D. and thor Straten, P. (2013) Immune-Suppressive Properties of the Tumor Microenvironment. Cancer Immunology, Immunotherapy, 62, 1137-1148. [Google Scholar] [CrossRef] [PubMed]
[8] Ott, P.A., Elez, E., Hiret, S., et al. (2017) Pembrolizumab in Pa-tients with Extensive-Stage Small-Cell Lung Cancer: Results from the Phase Ib KEYNOTE-028 Study. Journal of Clini-cal Oncology, 35, 3823-3829. [Google Scholar] [CrossRef] 
[9] Liu, S.V., Reck, M., Mansfield, A.S., et al. (2021) Updated Over-all Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Ate-zolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 39, 619-630. [Google Scholar] [CrossRef] 
[10] Goldman, J.W., Dvorkin, M., et al. (2021) CASPIAN Investigators. Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet Oncology, 22, 51-65. [Google Scholar] [CrossRef] 
[11] Foster, N.R., Qi, Y., Shi, Q., et al. (2011) Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer: Findings on the Basis of North Central Cancer Treatment Group Trials. Cancer, 117, 1262-1271. [Google Scholar] [CrossRef] [PubMed]
[12] Schiller, J.H., Adak, S., Cella, D., et al. (2001) Topotecan versus Observa-tion after Cisplatin plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19, 2114-2122. [Google Scholar] [CrossRef] 
[13] Jett, J.R., Schild, S.E., Kesler, K.A. and Kalemkerian, G.P. (2013) Treatment of Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, e400S-e419S. [Google Scholar] [CrossRef] [PubMed]
[14] Noda, K., Nishiwaki, Y., Kawahara, M., et al. (2002) Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. New England Journal of Medi-cine, 346, 85-91. [Google Scholar] [CrossRef] 
[15] Hermes, A., Bergman, B., Bremnes, R., et al. (2008) Irinotecan plus Carboplatin versus Oral Etoposide plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 26, 4261-4267. [Google Scholar] [CrossRef] 
[16] Zatloukal, P., Cardenal, F., Szczesna, A., et al. (2010) A Multicen-ter International Randomized Phase III Study Comparing Cisplatin in Combination with Irinotecan or Etoposide in Pre-viously Untreated Small-Cell Lung Cancer Patients with Extensive Disease. Annals of Oncology, 21, 1810-1816. [Google Scholar] [CrossRef] [PubMed]
[17] Rossi, A., Di Maio, M., Chiodini, P., et al. (2012) Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Indi-vidual Patient Data. Journal of Clinical Oncology, 30, 1692-1698. [Google Scholar] [CrossRef] 
[18] Ogino, H., Hanibuchi, M., Kakiuchi, S., et al. (2016) Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital. The Journal of Medical Investigation, 63, 286-293. [Google Scholar] [CrossRef] [PubMed]
[19] Goldie, J.H. and Coldman, A.J. (1979) A Mathematic Model for Relating the Drug Sensitivity of Tumors to Their Spontaneous Mutation Rate. Cancer Treatment Reports, 63, 1727-1733.
[20] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Re-views Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[21] Harvey, R.D. (2014) Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. Clinical Pharmacology & Therapeutics, 96, 214-223. [Google Scholar] [CrossRef] [PubMed]
[22] Oh, D.Y. and Fong, L. (2021) Cytotoxic CD4+ T Cells in Cancer: Ex-panding the Immune Effector Toolbox. Immunity, 54, 2701-2711. [Google Scholar] [CrossRef] [PubMed]
[23] Haanen, J.B.A.G. and Robert, C. (2015) Immune Checkpoint Inhibitors. In: Michielin, O. and Coukos, G., Eds., Immuno-Oncology. Progress in Tumor Research, Vol. 42, Karger Publishers, Basel, 55-66. [Google Scholar] [CrossRef] [PubMed]
[24] Ahn, M.J. (2019) Discussion: One Step Further toward Filling the Gap. IASLC World Conference on Lung Cancer, Barcelona, 7-10 September 2019.
[25] Reck, M., Luft, A., Szczesna, A., et al. (2016) Phase III Randomized Trial of Ipilimumab plus Etoposide and Platinum versus Placebo plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 34, 3740-3748. [Google Scholar] [CrossRef] 
[26] Horn, L., Mansfield, A.S., Szczęsna, A., et al. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2220-2229. [Google Scholar] [CrossRef] 
[27] Rudin, C.M., Awad, M.M., Navarro, A., et al. (2020) Pembroli-zumab or Placebo plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Ran-domized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 38, 2369-2379. [Google Scholar] [CrossRef] 
[28] Gadgeel, S.M., Pennell, N.A., Fidler, M.J., et al. (2018) Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology, 13, 1393-1399. [Google Scholar] [CrossRef] [PubMed]
[29] Morgensztern, D., Besse, B., Greillier, L., et al. (2019) Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results from the Phase II TRINITY Study. Clinical Cancer Research, 25, 6958-6966. [Google Scholar] [CrossRef] 
[30] Paz-Ares, L., Dvorkin, M., Chen, Y., et al. (2019) Durval-umab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet, 394, 1929-1939. [Google Scholar] [CrossRef] 
[31] Reck, M., Mok, T.S.K., Mansfield, A., et al. (2022) Brief Report: Exploratory Analysis of Maintenance Therapy in Patients with Extensive-Stage SCLC Treated First Line with Atezolizumab plus Carboplatin and Etoposide. Journal of Thoracic Oncology, 17, 1122-1129. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, X., Xing, H. and Liu, B. (2022) Current Status and Future Perspectives of Immune Checkpoint Inhibitors in Extensive-Stage Small Cell Lung Cancer. American Journal of Cancer Research, 12, 2447-2464.
[33] Antonia, S.J., López-Martin, J.A., Bendell, J., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, e270. [Google Scholar] [CrossRef] 
[34] Iams, W.T., Shi-uan, E., Meador, C.B., et al. (2019) Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC with Neurologic Paraneoplastic Syndromes. Journal of Thoracic Oncology, 14, 1970-1981. [Google Scholar] [CrossRef] [PubMed]
[35] Chung, H.C., Piha-Paul, S.A., et al. (2020) Pembrolizumab after Two or More Lines of Previous Therapy in Patients with Recurrent or Metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15, 618-627. [Google Scholar] [CrossRef] [PubMed]
[36] Ott, P.A., Bang, Y.-J., Piha-Paul, S.A., et al. (2019) T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Pre-dict Efficacy in Patients Treated with Pembrolizumab across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology, 37, 318-327. [Google Scholar] [CrossRef] 
[37] 庞连胜, 赵万春. 外周血淋巴细胞免疫表型检验在恶性肿瘤患者细胞免疫功能评价中的应用价值[J]. 国际免疫学杂志, 2019, 42(3): 280-284.
[38] 王玲, 邱志敏, 傅颖媛. DC-CIK细胞免疫治疗恶性肿瘤的研究进展[J]. 实用癌症杂志, 2017, 32(2): 345-348.
[39] Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine, 372, 2018-2028. [Google Scholar] [CrossRef] 
[40] 侯柏村, 刘婷婷, 李涛, 胡毅. LIPI评分与晚期胃癌患者免疫检查点抑制剂治疗疗效及预后的关系[J]. 解放军医学院学报, 2020, 41(5): 436-439+445.
[41] Sun, B., Hou, Q., Liang, Y., et al. (2022) Prognostic Ability of Lung Immune Prognostic Index in Limited-Stage Small Cell Lung Cancer. BMC Cancer, 22, Article No. 1233. [Google Scholar] [CrossRef] [PubMed]

为你推荐